Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer-Reference-Cited by-同舟云学术

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

Published:2012-03 Issue:3 Volume:20 Page:679-686
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Senzer Neil,Barve Minal,Kuhn Joseph,Melnyk Anton,Beitsch Peter,Lazar Martin,Lifshitz Samuel,Magee Mitchell,Oh Jonathan,Mill Susan W,Bedell Cynthia,Higgs Candice,Kumar Padmasini,Yu Yang,Norvell Fabienne,Phalon Connor,Taquet Nicolas,Rao Donald D,Wang Zhaohui,Jay Chris M,Pappen Beena O,Wallraven Gladice,Brunicardi F Charles,Shanahan David M,Maples Phillip B,Nemunaitis John

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference49 articles.

1. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity;Smyth;Adv Immunol,2006

2. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion;Schreiber;Science,2011

3. Deletion, but not anergy, is involved in TGF-beta-treated antigen-presenting cell-induced tolerance;Alard;Int Immunol,2003

4. TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells;Wahl;J Leukoc Biol,2004

5. Immunosuppressive networks in the tumour environment and their therapeutic relevance;Zou;Nat Rev Cancer,2005

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors;ESMO Open;2024-09

2. The Role of Furin and Its Therapeutic Potential in Cardiovascular Disease Risk;International Journal of Molecular Sciences;2024-08-26

3. Development and Prospects of Furin Inhibitors for Therapeutic Applications;International Journal of Molecular Sciences;2024-08-24

4. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

5. Boron Neutron Capture Therapy‐Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy;Advanced Science;2024-07-17